Nature Medicine, Published online: 04 March 2026; doi:10.1038/s41591-026-04255-3 This 5-year follow-up of the double-blinded, placebo-controlled phase 3 DEN-03-IB trial evaluating the efficacy and safety of the Butantan dengue vaccine in participants aged 2–59 years in Brazil found that a single dose of the vaccine was effective against DENV-1 and DENV-2, regardless of serostatus at baseline, and was safe.
Nature Medicine, Published online: 04 March 2026;
doi:10.1038/s41591-026-04255-3
This 5-year follow-up of the double-blinded, placebo-controlled phase 3 DEN-03-IB trial evaluating the efficacy and safety of the Butantan dengue vaccine in participants aged 2–59 years in Brazil found that a single dose of the vaccine was effective against DENV-1 and DENV-2, regardless of serostatus at baseline, and was safe.
— Source: Nature Medicine (https://www.nature.com/articles/s41591-026-04255-3)